

Application No.: 10/695,980
Amendment Dated: July 18, 2005
Reply to Examiner's Interview Dated: June 17, 2005

REMARKS

The undersigned attorney wishes to thank the Examiner for the courtesies extended during the telephonic Examiner's Interview conducted on June 17, 2005. During the Interview the Examiner recommended several amendments that would place the application in condition for allowance. With a view toward furthering prosecution, those amendments have been adopted.

Claim 7 has been cancelled, without prejudice.

As requested by the Examiner, claims 5, 6, and 8 have been amended to recite sequence identifiers (*i.e.*, SEQ ID NOs: 1-5 and 32) for the respective polynucleotide and polypeptide sequences. Support for these amendments is found in the Sequence Listing, as amended, and in the Specification at, for example, the following figures and description of the figures:

SEQ ID NO: 1	Fig. 7 and Pg. 3, Ins. 8-14
SEQ ID NO: 2	Fig. 8 and Pg. 3, Ins. 15-16
SEQ ID NO: 3	Fig. 9 and Pg. 3, Ins. 17-18
SEQ ID NO: 4	Fig. 10 and Pg. 3, Ins. 19-20
SEQ ID NO: 5	Fig. 11 and Pg. 3, Ins. 21-22
SEQ ID NO: 32	Fig. 32 and Pg. 6, Ins. 7-8

As requested by the Examiner, claim 5 has further been amended as to certain formal matters (*i.e.*, by replacing "said" with ~~the~~ and by spelling out GGPP synthase), which does not change the scope of the claims in any manner. Claim 5,

Application No.: 10/695,980

Amendment Dated: July 18, 2005

Reply to Examiner's Interview Dated: June 17, 2005

steps a) - d) have also been amended by replacing the "substantially homologous" language with specific hybridization conditions. Support for this amendment is found in the specification at, for example, page 35, lines 27-30.

As requested by the Examiner, claim 6 has further been amended as to certain formal matters (*i.e.*, by replacing "The" with --A--, "of" with --according to--, "said" with --the--, and "a" with --the--), which do not change the scope of the claims in any manner.

As requested by the Examiner, claim 8 has further been amended to remove its dependency from cancelled claim 7, and instead to depend from claim 6, to replace the term "bases" with --nucleotides--, to remove references to any of the Figures and to replace the recitation of nucleotides "4316-3405" with --3405-4316--. These amendments are strictly formal in nature and do not change the scope of the claims in any manner.

It is submitted that no new matter has been introduced by the foregoing amendments. Approval and entry of the amendments respectfully is requested.

Application No.: 10/695,980
Amendment Dated: July 18, 2005
Reply to Examiner's Interview Dated: June 17, 2005

In view of the agreement reached with the Examiner at the interview conducted on June 17, 2005, favorable action on the merits, including entry of the amendments and allowance of all the claims, respectfully is requested. If the Examiner has any questions regarding this paper, please contact the undersigned attorney.

I hereby certify that this correspondence is being transmitted to the U.S. Patent and Trademark Office via facsimile transmission and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, at (571) 273-8300 on July 18, 2005.

Charles M. Avigliano
Charles M. Avigliano, Reg. No. 52,578

Respectfully submitted,

By: Charles M. Avigliano
Charles M. Avigliano
Registration No. 52,578
BRYAN CAVE LLP
1290 Avenue of the Americas
New York, NY 10104
Phone: (212) 541-2000
Fax: (212) 541-4630